Ryan Murtagh, MD
Diagnostic Neuroimaging · El Segundo, CANPI 1548396997
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $253,977 of the $255,658 with a category attached, or 99.3%. Merck accounts for 64.4% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2021 at $112,982 and has fallen 99.9% since, to $155 in 2025. Among diagnostic neuroimaging clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 135 payments — averaging $1893.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$165K
- Boehringer Ingelheim RCV GmbH & Co KG$62K
- Stryker$28K
- Penumbra, Inc.$882
- Bracco Diagnostics Inc.$359
- Thrombolex, Inc.$138
- plus $303 from 6 others
Across 82 payments — averaging $7489.94 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$284K
- Boehringer Ingelheim Espana S.A.$198K
- Takeda Pharmaceuticals U.S.A., Inc.$80K
- Regeneron$25K
- Biomarin Pharmaceutical Inc.$11K
- Genentech, Inc.$9K
- plus $7K from 1 others
What the payments were for
- Consulting fees$253,97799%
- Food & beverage$1,6821%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 100 | $164,589 |
| Boehringer Ingelheim RCV GmbH & Co KG | 4 | $61,585 |
| Stryker | 10 | $27,803 |
| Penumbra, Inc. | 7 | $882 |
| Bracco Diagnostics Inc. | 7 | $359 |
| Thrombolex, Inc. | 1 | $138 |
| AstraZeneca | 1 | $125 |
| Philips North America LLC | 1 | $61 |
| Boston Scientific | 1 | $53 |
| Immedica Pharma US, Inc. | 1 | $23 |
| Bayer | 1 | $21 |
| Neuropace, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LENVIMA$111,983
- PRADAXA$58,620
- MK-4280$35,220
- CASCADIA INTERBODY SYSTEM$18,813
- KEYTRUDA$8,537
- CASCADIA$8,080
- RAVINE$8,080
- EVEREST$8,080
- CAPRI CORPECTOMY CAGE SYSTEM$910
- Indigo$448
- Indigo System$278
- Bashir Endovascular Catheter$138
- ULTOMIRIS$125
- MULTIHANCE$104
How this compares
$255,658 in reported general payments places this provider in the 95th percentile of 26 diagnostic neuroimaging providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other diagnostic neuroimaging in El Segundo
- Jeremy HeitStanford$224K
- Daniel ChowOrange$75K
- Nancy PhamStanford$71K
- Seena DehkharghaniStanford$16K
- Gregory ZaharchukStanford$10K
- Laila MaladWestlake Village$6K
- Michael ZeinehStanford$5K
- Michael IvStanford$4K
- Andrew ChiuStanford$576
- Dale JamisonStanford$254
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.